|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500102717 |
|
最近更新日期: Date of Last Refreshed on: |
2025-05-19 15:17:51 |
|
注册时间: Date of Registration: |
2025-05-19 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
星状神经节阻滞对急诊眼外伤手术患者创伤后应激障碍的影响:随机双盲安慰剂对照试验 |
|
Public title: |
Effect of stellate ganglion block on posttraumatic stress disorder in patients undergoning emergency ocular trauma surgery: a randomized double-blind placebo-controlled trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
星状神经节阻滞对急诊眼外伤手术患者创伤后应激障碍的影响:随机双盲安慰剂对照试验 |
|
Scientific title: |
Effect of stellate ganglion block on posttraumatic stress disorder in patients undergoning emergency ocular trauma surgery: a randomized double-blind placebo-controlled trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
高旗 |
研究负责人: |
朱蕾 |
|
Applicant: |
Qi Gao |
Study leader: |
Lei Zhu |
|
申请注册联系人电话: Applicant telephone: |
+86 156 3249 1278 |
研究负责人电话:
Study leader's |
+86 186 1778 9652 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
799566191@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
leilei12192021@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
河北省保定市莲池区五四东路443号 |
研究负责人通讯地址: |
河北省保定市莲池区五四东路443号 |
|
Applicant address: |
No.443 Wusi East Road, Lianchi District, Baoding,Hebei |
Study leader's address: |
No.443 Wusi East Road, Lianchi District, Baoding,Hebei |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
保定市第一中心医院 |
||
|
Applicant's institution: |
the First Central Hospital of Baoding |
||
|
研究负责人所在单位: |
保定市第一中心医院 |
||
|
Affiliation of the Leader: |
the First Central Hospital of Baoding |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
会审[2025]第030号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
保定市第一中心医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Baoding First Central Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-05-14 00:00:00 | ||
|
伦理委员会联系人: |
陈宏伟 |
||
|
Contact Name of the ethic committee: |
Hongwei Chen |
||
|
伦理委员会联系地址: |
河北省保定市莲池区五四东路443号 |
||
|
Contact Address of the ethic committee: |
No.443 Wusi East Road, Lianchi District, Baoding,Hebei |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 312 597 6679 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
保定市第一中心医院 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
the First Central Hospital of Baoding |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
河北省保定市莲池区五四东路443号 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
No.443 Wusi East Road, Lianchi District, Baoding,Hebei |
||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
1.江苏省中医药科技发展计划项目(MS2024082) 2.保定市科技发展计划项目(2241ZF252) |
||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
1.Jiangsu Province Traditional Chinese Medicine Science and Technology Development Program Project (MS2024082) 2. Baoding Science and Technology Development Plan Project (2241ZF252) |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
创伤后应激障碍 |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Posttraumatic stress disorder |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
评价星状神经节阻滞对急诊眼外伤手术患者创伤后应激障碍的影响 |
||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
Evaluate the effect of stellate ganglion block on post-traumatic stress disorder in patients undergoing emergency ocular trauma surgery. |
||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
1.18岁或以上。 2.急性单侧或双侧眼外伤,拟在全麻下手术治疗。 3.美国麻醉医师协会(ASA)I-III E。 4.在患者及其家属同意的情况下,提供知情同意。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
1.Age 18 or older. 2.Acute unilateral or bilateral ocular trauma and scheduled for surgery under general anesthesia. 3.American Society of Anesthesiologists (ASA) physical status I-III E. 4.Provided informed consent, with approval from both patients and their families. |
||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
1.罗哌卡因过敏。 2.颈部皮肤感染。 3.合并严重的神经或精神障碍,无法接受评估者。 4.颅脑或脊髓损伤。 5.休克失代偿。 6.合并多发和复杂性损伤,需要同时实施多外科手术。 7.严重房室传导阻滞或慢性心律失常,基线心率低于50次/分。 8.严重的视觉、听觉或语言障碍,无法完成评估。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
1.A known allergy to ropivacaine. 2.Infection of the skin on the neck. 3.Combine severe neurological or mental disorders unable to undergo assessmtent. 4.Craniocerebral or spinal cord injury. 5.Shock decompensation. 6.Associated with multiple and complex injuries and requiring concurrent implementation of multiple surgical procedures. 7.Severe atrioventricular block or bradyarrhythmia with a baseline heart rate lower than 50 beats/min. 8.Severe visual, hearing, or speech impairments that prevent the completion of assessment. |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-05-22 00:00:00至 To 2026-05-22 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-05-22 00:00:00 至 To 2026-05-22 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
按照年龄分层区组随机化,符合随机标准的患者将给予计算机生成的随机号并以1∶1的比例随机分入两组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Stratified block randomization was conducted by age. Patients meeting the randomization criteria were given computer-generated random numbers and randomly assigned to the two groups at a ratio of 1∶1. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
根据随机数字信息进行盲法,对试验药物和对照药物进行分类和标注。本试验采用双盲设计,使用与试验药物外观相同的安慰剂,生理盐水。患者的临床管理和数据收集按顺序编号,并由未直接参与的医务人员披露。 |
|
Blinding: |
Blinding was conducted based on random number information to classify and label the test drugs and control drugs. This trial adopted a double-blind design and used a placebo with the same appearance as the test drug and normal saline. The clinical management and data collection of patients were numbered in sequence and disclosed by medical staff who were not directly involved. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
待研究结束,相关研究结果发表后,若其他研究者因相关学术研究需要,在不对受试者个人隐私产生威胁或获得受试者同意后,可通过与主要研究者联系,获取原始数据。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the research is completed and the relevant research results are published, if other researchers need to conduct related academic research and do not pose a threat to the personal privacy of the subjects or obtain the consent of the subjects, they can obtain the original data by contacting the principal researcher. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |